Activity Description
Antiplatelet therapy is an established tool to prevent thrombosis in patients undergoing percutaneous coronary intervention (PCI). Unfortunately, however, thrombotic events continue to occur. Some patients receiving antiplatelet therapy may not be fully protected due to antiplatelet resistance. Suboptimal use of antiplatelet therapy has also been reported. This activity will provide a forum to discuss therapeutic issues involving antiplatelet therapy during and following PCI. Strategies to address the unmet need will be highlighted.

Moderator
Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP 
Associate Director, Cardiovascular Coordinating Center
Staff, Cardiac, Peripheral, and Carotid Intervention
Associate Professor of Medicine
Department of Cardiovascular Medicine
Cleveland Clinic
Cleveland, Ohio   

Presented By
E. Magnus Ohman, MD, FACC
Professor of Medicine
Duke University School of Medicine
Director, Program for Advanced Coronary Disease
Duke University Medical Center
Durham, North Carolina 

Stephen D. Wiviott, MD
Associate Physician, Cardiovascular Division
Brigham and Women's Hospital
Investigator, TIMI Study Group
Harvard Medical School
Boston, Massachusetts 

Intended Audience 
This CME activity is designed for cardiologists, interventional cardiologists, pharmacists, nurses, and other health care professionals involved in the care of patients with atherothrombotic disease.

Learning Objectives

1. Recognize factors that influence platelet activation and their importance to clinical practice and patient care
2. List the benefits of antiplatelet therapy in patients with atherothrombotic disease undergoing PCI
3. List the duration of oral antiplatelet therapy following PCI as recommended by clinical practice guidelines
4. Identify the role of novel antiplatelet therapy in the management of patients undergoing PCI

Accreditation Statements/Credit Designation:
i3 CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

i3 CME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.  

The University of Florida College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 1 contact hour (0.1 CEU) in states that recognize ACPE.

To receive live credit, you must attend the entire session and complete the evaluat